
FUSN
Healthcare · Biotechnology · $1.83B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 14, 2024 | Before the open | -0.37 | -0.40 | -8.6% |
| Mar 20, 2024 | After the close | -0.34 | -0.39 | -14.7% |
| Nov 7, 2023 | Before the open | -0.40 | -0.25 | +37.5% |
| Aug 8, 2023 | Before the open | -0.39 | -0.38 | +2.6% |
| May 11, 2023 | Before the open | -0.32 | -0.45 | -40.6% |
| Mar 16, 2023 | Before the open | -0.56 | -0.55 | +1.8% |
| Nov 8, 2022 | Before the open | -0.50 | -0.55 | -10.0% |
| Aug 9, 2022 | Before the open | -0.53 | -0.44 | +17.0% |
| May 10, 2022 | Before the open | -0.48 | -0.46 | +4.2% |
| Mar 17, 2022 | Before the open | -0.47 | -0.40 | +14.9% |
| Nov 9, 2021 | Before the open | -0.60 | -0.45 | +25.0% |
| Aug 10, 2021 | Before the open | -0.39 | -0.63 | -61.5% |
| May 11, 2021 | Before the open | -0.29 | -0.42 |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target…
| -44.8% |
| Mar 25, 2021 | Before the open | -0.19 | -0.32 | -68.4% |
| Nov 10, 2020 | Before the open | -0.14 | -0.24 | -71.4% |
| Aug 11, 2020 | Before the open | -0.50 | -18.91 | -3682.0% |
| Jun 26, 2020 | After the close | — | -0.29 | — |